"Prostatic Hyperplasia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Descriptor ID |
D011470
|
| MeSH Number(s) |
C12.294.565.500
|
| Concept/Terms |
Adenoma, Prostatic- Adenoma, Prostatic
- Adenomas, Prostatic
- Prostatic Adenomas
- Prostatic Adenoma
|
Below are MeSH descriptors whose meaning is more general than "Prostatic Hyperplasia".
Below are MeSH descriptors whose meaning is more specific than "Prostatic Hyperplasia".
This graph shows the total number of publications written about "Prostatic Hyperplasia" by people in this website by year, and whether "Prostatic Hyperplasia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 0 | 2 |
| 1995 | 2 | 1 | 3 |
| 1996 | 1 | 0 | 1 |
| 1997 | 2 | 0 | 2 |
| 1998 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 3 | 0 | 3 |
| 2009 | 1 | 1 | 2 |
| 2010 | 3 | 1 | 4 |
| 2011 | 2 | 0 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prostatic Hyperplasia" by people in Profiles.
-
Gao BM, Saadat S, Choi EJH, Jiang J, Das AK. How I Do It: Holmium laser cystolitholapaxy and enucleation of the prostate for benign prostatic hyperplasia. Can J Urol. 2024 Jun; 31(3):11904-11907.
-
Doolin J, Reese ZA, Mukamal KJ. National trends in the use of PSA, urinalysis, and digital rectal exam for evaluation of lower urinary tract symptoms in men. World J Urol. 2021 Mar; 39(3):855-860.
-
Fong LY, Jing R, Smalley KJ, Wang ZX, Taccioli C, Fan S, Chen H, Alder H, Huebner K, Farber JL, Fiehn O, Croce CM. Human-like hyperplastic prostate with low ZIP1 induced solely by Zn deficiency in rats. Proc Natl Acad Sci U S A. 2018 11 20; 115(47):E11091-E11100.
-
Gandhi SD, Patel SA, Maltenfort M, Anderson DG, Vaccaro AR, Albert TJ, Rihn JA. Patient and surgical factors associated with postoperative urinary retention after lumbar spine surgery. Spine (Phila Pa 1976). 2014 Oct 15; 39(22):1905-9.
-
Chancellor MB, Elovic E, Esquenazi A, Naumann M, Segal KR, Schiavo G, Smith CP, Ward AB. Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions. Toxicon. 2013 Jun 01; 67:129-40.
-
Kelly DC, Das A. Holmium laser enucleation of the prostate technique for benign prostatic hyperplasia. Can J Urol. 2012 Feb; 19(1):6131-4.
-
Schenk JM, Kristal AR, Arnold KB, Tangen CM, Neuhouser ML, Lin DW, White E, Thompson IM. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. Am J Epidemiol. 2011 Jun 15; 173(12):1419-28.
-
Liu XS, Folia C, Gomella LG. Pharmacology for common urologic diseases: 2011 review for the primary care physician. Can J Urol. 2011 Apr; 18 Suppl:24-38.
-
Kristal AR, Price DK, Till C, Schenk JM, Neuhouser ML, Ockers S, Lin DW, Thompson IM, Figg WD. Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Prostate. 2010 May 01; 70(6):584-90.
-
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010 Apr 1; 362(13):1192-202.